Why is West Pharmaceutical Services (WST) stock up today?

West Pharmaceutical Services stock is up about 0.38% to $359 today, trading within a day range of $354.19 to $360.74. The move is modest but is supported by a cluster of positive analyst actions: TD Cowen raised its price target on the stock to $410 from $365 while maintaining a Buy rating, and Argus Research separately lifted its target to $393. Analyst upgrades of this kind tend to draw incremental buying interest from institutional investors who track consensus price targets.

Adding to the positive backdrop, West Pharmaceutical Services filed an 8-K disclosing that it has entered into multiple amended distribution and cross-licensing agreements with Daikyo Seiko — a longstanding partner in drug-packaging components. Expanded partnership terms can signal deeper revenue commitments and volume arrangements, which the market tends to view favorably for a company whose business depends heavily on recurring contracts with pharmaceutical manufacturers.

The broader S&P 500 is also up 0.38% today, meaning West Pharmaceutical is roughly moving in step with the overall market rather than significantly outperforming it. On the macro front, Core PPI data released on July 15 came in at a forecast of 0.3%, following the July 14 CPI and Fed Chairman Warsh testimony — a relatively stable inflationary backdrop that has not disrupted healthcare-adjacent industrials.

West Pharmaceutical's last reported quarter showed earnings per share of $2.13 against an estimate of roughly $1.68 — a significant beat — alongside revenue of $844.9 million. Revenue growth stands at 21% and earnings growth at 56.1% on a trailing basis, with the next quarterly earnings report scheduled for July 23. The stock's trailing P/E ratio of 48.1 reflects a premium valuation consistent with its recent growth profile.